Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.25%
1,104.10
+2.73
+0.25%
—1,101.371,103.631,105.311,091.41——
SIXC
Communications
SIXC
Communications
SIXC
-1.50%
604.16
-9.19
-1.50%
—613.35613.35613.35601.49——
SIXE
Energy
SIXE
Energy
SIXE
-0.09%
1,197.81
-1.02
-0.09%
—1,198.831,199.681,199.751,182.41——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.88%
1,740.41
-15.54
-0.88%
—1,755.951,754.061,756.031,734.69——
SIXM
Financials
SIXM
Financials
SIXM
-0.64%
634.44
-4.07
-0.64%
—638.51637.41637.41633.05——
SIXR
Staples
SIXR
Staples
SIXR
-0.31%
840.90
-2.62
-0.31%
—843.52843.35846.40837.93——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.38%
215.13
-0.82
-0.38%
—215.95215.95216.84215.06——
SIXT
Technology
SIXT
Technology
SIXT
+2.86%
3,228.71
+89.80
+2.86%
—3,138.913,189.303,230.853,174.76——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.16%
935.87
+1.50
+0.16%
—934.37934.72938.26927.50——
SIXV
Health care
SIXV
Health care
SIXV
-1.37%
1,457.12
-20.31
-1.37%
—1,477.431,474.121,474.121,451.80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.83%
2,399.84
+19.65
+0.83%
—2,380.192,389.342,403.042,380.47——
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
$24.10
-0.74%
(-0.18) 1D
$24.10
0.00% (0.00)
Pre-market
Closed: Apr 24, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RARE...
Open
$24.37
High
$24.44
Low
$23.68
Mkt. cap
2.37B
Avg. vol.
2.04M
Volume
209.00
52-wk high
$42.37
52-wk low
$18.29
EPS
-$5.83
Beta
0.25
Shares outstanding
98.32M
No. of employees
1K
News stories
From sources across the web
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases. Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami. Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOEmil Kakkis
Employees1.37K
Founded2010
HeadquartersNovato, California, United States
SectorBiotechnology
Websiteultragenyx.com
Next call in 8 days
Tue, May 5, 5:00 PM
Fiscal Period
Q1 2026
Normalized EPS / Estimate
-/ (-1.46 est.)USD
Revenue / Estimate
-/ (158.41M est.)USD
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earningsInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
139.29M
166.50M
159.93M
207.28M
Cost of goods sold
194.43M
187.74M
244.20M
232.62M
Cost of revenue
194.43M
187.74M
244.20M
232.62M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
87.80M
86.65M
86.62M
87.94M
Operating expense
87.80M
86.65M
86.62M
87.94M
Total operating expenses
282.23M
274.38M
330.82M
320.56M
Operating income
-142.94M
-107.89M
-170.89M
-113.28M
Other non operating income
837.00K
2.14M
-1.04M
-934.00K
EBT including unusual items
-149.77M
-114.00M
-179.54M
-127.69M
EBT excluding unusual items
-149.61M
-114.00M
-180.22M
-127.17M
Income tax expense
1.31M
947.00K
873.00K
870.00K
Effective tax rate
-0.87%
-0.83%
-0.49%
-0.68%
Other operating expenses
-
-
-
-
Net income
-151.08M
-114.95M
-180.41M
-128.56M
Net profit margin
-108.46%
-69.04%
-112.81%
-62.02%
Earnings per share
-1.57
-1.17
-1.81
-1.29
Interest and investment income
6.83M
5.79M
5.86M
6.51M
Interest expense
-14.34M
-14.04M
-14.15M
-19.47M
Net interest expenses
-7.51M
-8.25M
-8.28M
-12.96M
Depreciation and amortization charges
-
-
-
-
EBITDA
-133.95M
-99.27M
-162.28M
-104.50M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer